Grown Rogue International (GRUSF) Income from Discontinued Operations (2013 - 2020)
Grown Rogue International (GRUSF) posted quarterly Income from Discontinued Operations of 90150.0 for Q2 2020, down 443.89% quarter-over-quarter from 16575.0 in Q1 2020.
Grown Rogue International (GRUSF) Income from Discontinued Operations (2013 - 2020) Analysis & Trends
Grown Rogue International's Income from Discontinued Operations history runs 4 years deep, the most recent figure standing at 90150.0 for Q2 2020.
- In Q2 2020, Income from Discontinued Operations changed N/A year-over-year to 90150.0; the TTM figure through Apr 2020 stood at 81340.17 (changed N/A YoY), while the FY2019 annual figure was 121920.0, changed N/A from the prior year.
- Income from Discontinued Operations for Q2 2020 stood at 90150.0, down from 16575.0 in the prior quarter.
- The five-year high for Income from Discontinued Operations was 16575.0 in Q1 2020, with the low at 90150.0 in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Discontinued) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.33 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.15 Bn | 19.48 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.74 Bn | 11.21 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Grown Rogue International | 110.47 Mn | 98.93 Mn | 5.37 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2020 | -90,150.00 |
| Jan 31, 2020 | -16,575.00 |
| Nov 30, 2015 | -2,956.19 |
| Nov 30, 2014 | 191,021.36 |
| May 31, 2013 | 108,173.35 |